Department of Cardiology, Hospital Clínico Universitario de Valencia (INCLIVA), Valencia, Spain.
University of Vermont, Larner College of Medicine, Department of Medicine, Burlington, VT, USA.
Eur J Heart Fail. 2024 Jan;26(1):167-176. doi: 10.1002/ejhf.3107. Epub 2024 Jan 2.
Emerging evidence suggests a beneficial effect of higher heart rates in some patients with heart failure with preserved ejection fraction (HFpEF). This study aimed to evaluate the impact of higher backup pacing rates in HFpEF patients with preexisting pacemaker systems that limit pacemaker-mediated dyssynchrony across left ventricular (LV) volumes and LV ejection fraction (LVEF).
This is a post-hoc analysis of the myPACE clinical trial that evaluated the effects of personalized accelerated pacing setting (myPACE) versus standard of care on changes in Minnesota Living with Heart Failure Questionnaire (MLHFQ) score, N-terminal pro-brain natriuretic peptide (NT-proBNP), pacemaker-detected activity levels, and atrial fibrillation (AF) burden in patients with HFpEF with preexisting pacemakers. Between-treatment comparisons were performed using linear regression models adjusting for the baseline value of the exposure (ANCOVA design). This study included 93 patients with pre-trial transthoracic echocardiograms available (usual care n = 49; myPACE n = 44). NT-proBNP levels and MLHFQ scores improved in a higher magnitude in the myPACE group at lower indexed LV end-diastolic volumes (iLVEDV) (NT-proBNP-iLVEDV interaction p = 0.006; MLHFQ-iLVEDV interaction p = 0.068). In addition, personalized accelerated pacing led to improved changes in activity levels and NT-proBNP, especially at higher LVEF (activity levels-LVEF interaction p = 0.009; NT-proBNP-LVEF interaction p = 0.058). No evidence of heterogeneity was found across LV volumes or LVEF for pacemaker-detected AF burden.
In the post-hoc analysis of the myPACE trial, we observed that the benefits of a personalized accelerated backup pacing on MLHFQ score, NT-proBNP, and pacemaker-detected activity levels appear to be more pronounced in patients with smaller iLVEDV and higher LVEF.
越来越多的证据表明,在射血分数保留的心力衰竭(HFpEF)患者中,较高的心率可能有益。本研究旨在评估在左心室(LV)容积和 LV 射血分数(LVEF)限制起搏器介导的不同步的预起搏患者中,较高的备用起搏率对 HFpEF 患者的影响。
这是 myPACE 临床试验的事后分析,该试验评估了个性化加速起搏设置(myPACE)与标准治疗对 HFpEF 伴预起搏患者的明尼苏达州心力衰竭生活质量问卷(MLHFQ)评分、N 末端脑利钠肽前体(NT-proBNP)、起搏器检测到的活动水平和心房颤动(AF)负担变化的影响。使用调整暴露基线值的线性回归模型(ANCOVA 设计)进行组间比较。本研究纳入了 93 例有试验前经胸超声心动图的患者(常规治疗组 n=49;myPACE 组 n=44)。在较低的指数化 LV 舒张末期容积(iLVEDV)时,myPACE 组的 NT-proBNP 水平和 MLHFQ 评分改善幅度更大(NT-proBNP-iLVEDV 交互作用 p=0.006;MLHFQ-iLVEDV 交互作用 p=0.068)。此外,个性化加速起搏可改善活动水平和 NT-proBNP 的变化,尤其是在 LVEF 较高时(活动水平-LVEF 交互作用 p=0.009;NT-proBNP-LVEF 交互作用 p=0.058)。在 LV 容积或 LVEF 上,起搏器检测到的 AF 负担没有发现异质性。
在 myPACE 试验的事后分析中,我们观察到个性化加速备用起搏对 MLHFQ 评分、NT-proBNP 和起搏器检测到的活动水平的益处,在 iLVEDV 较小和 LVEF 较高的患者中更为明显。